Wang xiaoyang, deputy director of the consumer goods
Posted: Wed Feb 12, 2025 9:49 am
The current positive detection rate of respiratory syncytial virus in children aged 0-4 years old shows a fluctuating upward trend.
The positive rates of rhinovirus, mycoplasma pneumoniae and adenovirus tests showed a downward trend.
The novel coronavirus and other respiratory pathogens are generally at low prevalence levels.
Overall, respiratory infectious diseases this winter and spring still showed a trend of alternating or overlapping epidemics, all caused by known pathogens, and no new infectious diseases emerged. It is expected that the overall epidemic intensity and medical pressure this year will not be higher than last year. Thanks!
Cctv reporter: recently, respiratory diseases such as influenza have been prevalent, and the demand for medicines among the public has increased significantly. What is the current overall production and supply situation of relevant drugs? In addition, what has the ministry of industry and information technology done to stabilize production and supply?
Industry department of the ministry of industry and bc data mexico information technology  : thank you for your question. My country is a major pharmaceutical industry country with 12,500 industrial enterprises above a certain scale. The industrial chain is resilient, with large production capacity and great potential for capacity expansion. It has the ability to rapidly increase production on a large scale, especially for drugs related to respiratory diseases.
It has a complete range of products and large production capacity and output to meet relevant needs. From the perspective of production and supply, the ministry of industry and information technology has systematically sorted out the production capacity and output of respiratory disease-related drugs that are of concern to the public, including antipyretics and analgesics, antibiotics, traditional chinese medicine, small molecule antiviral drugs, etc. Overall, the supply is sufficient and the market is stable.
For example, our daily production capacity of oseltamivir phosphate has reached 1.56 million doses, and our inventory exceeds 47 million doses, of which the inventory of granule dosage forms for children exceeds 16 million doses; the daily production capacity of lianhua qingwen has reached 120 million tablets, and our inventory exceeds 86 million boxes; the daily production capacity of ibuprofen has reached 150 million tablets, and these categories have the ability to increase and expand production.
The positive rates of rhinovirus, mycoplasma pneumoniae and adenovirus tests showed a downward trend.
The novel coronavirus and other respiratory pathogens are generally at low prevalence levels.
Overall, respiratory infectious diseases this winter and spring still showed a trend of alternating or overlapping epidemics, all caused by known pathogens, and no new infectious diseases emerged. It is expected that the overall epidemic intensity and medical pressure this year will not be higher than last year. Thanks!
Cctv reporter: recently, respiratory diseases such as influenza have been prevalent, and the demand for medicines among the public has increased significantly. What is the current overall production and supply situation of relevant drugs? In addition, what has the ministry of industry and information technology done to stabilize production and supply?
Industry department of the ministry of industry and bc data mexico information technology  : thank you for your question. My country is a major pharmaceutical industry country with 12,500 industrial enterprises above a certain scale. The industrial chain is resilient, with large production capacity and great potential for capacity expansion. It has the ability to rapidly increase production on a large scale, especially for drugs related to respiratory diseases.
It has a complete range of products and large production capacity and output to meet relevant needs. From the perspective of production and supply, the ministry of industry and information technology has systematically sorted out the production capacity and output of respiratory disease-related drugs that are of concern to the public, including antipyretics and analgesics, antibiotics, traditional chinese medicine, small molecule antiviral drugs, etc. Overall, the supply is sufficient and the market is stable.
For example, our daily production capacity of oseltamivir phosphate has reached 1.56 million doses, and our inventory exceeds 47 million doses, of which the inventory of granule dosage forms for children exceeds 16 million doses; the daily production capacity of lianhua qingwen has reached 120 million tablets, and our inventory exceeds 86 million boxes; the daily production capacity of ibuprofen has reached 150 million tablets, and these categories have the ability to increase and expand production.